CyPass
Device
Alcon Research Ltd
Total Payments
$3.8M
Transactions
6,759
Doctors
2,773
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $24,694 | 23 | 0 |
| 2022 | $71,156 | 58 | 1 |
| 2021 | $120,691 | 106 | 1 |
| 2020 | $72,064 | 60 | 2 |
| 2019 | $241,261 | 147 | 19 |
| 2018 | $1.5M | 4,010 | 2,042 |
| 2017 | $1.8M | 2,355 | 1,124 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.5M | 1,222 | 40.0% |
| Consulting Fee | $802,388 | 467 | 20.9% |
| Royalty or License | $785,675 | 9 | 20.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $359,738 | 117 | 9.4% |
| Food and Beverage | $250,337 | 4,658 | 6.5% |
| Travel and Lodging | $107,007 | 284 | 2.8% |
| Gift | $166.72 | 2 | 0.0% |
Payments by Type
General
$2.3M
5,537 transactions
Research
$1.5M
1,222 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Observational Multicenter Clinical Study to Assess the Long-Term Safety of the Transcend CyPass Micro-Stent Glaucoma Implant in Patients With primary Open Angle Glaucoma who have Completed participation in the COMPASS Trial (A02803 Transcend Cypass) | Alcon Research Ltd | $453,361 | 3 |
| Post Approval Study of the Transcend CyPass Glaucoma Implant in Patients with Open Angle Glaucoma Undergoing Cataract Surgery (Transcend CyPass) | Alcon Research Ltd | $430,923 | 2 |
| An Observational Multicenter Clinical Study to Provide Additional Long- Term Follow-up Beyond 60 Months for Subjects Implanted with a CyPass Micro-Stent in the COMPASS Trial | Alcon Research LLC | $200,887 | 1 |
| Post Approval Study of the Transcend CyPass Glaucoma Implant in Patients with Open Angle Glaucoma Undergoing Cataract Surgery | Alcon Research LLC | $92,993 | 0 |
| Retrospective Review of Phacoemulsification Combined with the CyPass Micro-Stent versus Phacoemulsification Combined with the Glaukos iStent for the Treatment of Primary Open Angle Glaucoma | Alcon Research Ltd | $58,430 | 0 |
| Post Approval Study of the Transcend CyPass Glaucoma Implant in Patients with Open Angle Glaucoma Undergoing Cataract Surgery (Transcend CyPass) | Alcon Research LLC | $55,507 | 0 |
| A Retrospective Comparative Study of Bilaterally Implanted CyPass Micro-Stent and iStent in Patients From the COMPASS Trial | Alcon Research Ltd | $48,115 | 0 |
| Retrospective Review of the Efficacy of the Cypass Micro-Stent as a Stand-Alone Procedure for the Treatment of Primary Open Angle Glaucoma | Alcon Research Ltd | $39,019 | 0 |
| Retrospective study evaluating Cypass surgical outcomes at a single subspecialty glaucoma practice, post-FDA approval | Alcon Research LLC | $30,375 | 1 |
| Retrospective study evaluating Cypass surgical outcomes at a single subspecialty glaucoma practice, post-FDA approval | Alcon Research Ltd | $30,375 | 1 |
| Effect of CyPass implantation with concurrent cataract surgery on the accuracy of intraocular lens calculations in patients with open angle glaucoma | Alcon Research LLC | $22,575 | 0 |
| Effect of CyPass implantation with concurrent cataract surgery on the accuracy of intraocular lens calculations in patients with open angle glaucoma | Alcon Research Ltd | $22,575 | 0 |
| Long Term Efficacy of the CyPass Micro-Stent Combined with Phacoemulsification | Alcon Research LLC | $21,090 | 0 |
| Long Term Efficacy of the CyPass Micro-Stent Combined with Phacoemulsification | Alcon Research Ltd | $21,090 | 0 |
| An Observational Multicenter Clinical Study to Provide Additional Long Term Follow up Beyond 60 Months for Subjects Implanted with a CyPass MicroStent in the COMPASS Trial | Alcon Research LLC | $10,555 | 0 |
| A Retrospective Comparative Study of Bilaterally Implanted CyPass Micro-Stent and iStent in Patients From the COMPASS Trial | Alcon Research LLC | $990.94 | 0 |
Top Doctors Receiving Payments for CyPass
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cleveland, OH | $1.5M | 1,205 |
| , M.D. MPH | Ophthalmology | San Mateo, CA | $479,540 | 13 |
| , MD | Ophthalmology | San Francisco, CA | $265,656 | 2 |
| , M.D | Ophthalmology | Springdale, AR | $165,482 | 113 |
| , M.D | Ophthalmology | Eugene, OR | $160,908 | 36 |
| , MD | Ophthalmology | Stanford, CA | $121,447 | 35 |
| , MD | Ophthalmology | Sacramento, CA | $90,783 | 53 |
| , M.D | Ophthalmology | La Jolla, CA | $82,553 | 106 |
| , M.D | Glaucoma Specialist | Fort Worth, TX | $72,169 | 55 |
| , M.D, MPH | Ophthalmology | Dallas, TX | $61,030 | 9 |
| , M.D | Ophthalmology | Ypsilanti, MI | $59,450 | 96 |
| , M.D | Ophthalmology | New York, NY | $53,889 | 71 |
| , MD | Glaucoma Specialist | Saint Louis, MO | $48,883 | 67 |
| , MD | Ophthalmology | Oklahoma City, OK | $45,350 | 60 |
| , MD | Specialist | Pittsburgh, PA | $36,157 | 32 |
| , MD | Ophthalmology | Newark, NJ | $30,333 | 22 |
| , M.D | Ophthalmology | Minneapolis, MN | $28,377 | 28 |
| , M.D | Specialist | Boston, MA | $26,020 | 20 |
| , M.D | Ophthalmology | Cape Coral, FL | $22,135 | 18 |
| , MD | Ophthalmology | Baltimore, MD | $22,062 | 20 |
| , M.D | Ophthalmology | Oklahoma City, OK | $20,895 | 31 |
| , MD | Ophthalmology | Norfolk, VA | $17,731 | 27 |
| , M.D | Ophthalmology | Bloomington, MN | $12,768 | 1 |
| , MD | Ophthalmology | Aurora, CO | $12,540 | 11 |
| , M.D | Glaucoma Specialist | Sacramento, CA | $12,501 | 19 |
Ad
Manufacturing Companies
- Alcon Research Ltd $2.3M
- Alcon Laboratories Inc $982,510
- Alcon Research LLC $527,381
- Alcon Vision LLC $2,771
- Alcon Puerto Rico Inc $62.92
Product Information
- Type Device
- Total Payments $3.8M
- Total Doctors 2,773
- Transactions 6,759
About CyPass
CyPass is a device associated with $3.8M in payments to 2,773 healthcare providers, recorded across 6,759 transactions in the CMS Open Payments database. The primary manufacturer is Alcon Research Ltd.
Payment data is available from 2017 to 2023. In 2023, $24,694 was paid across 23 transactions to 0 doctors.
The most common payment nature for CyPass is "Unspecified" ($1.5M, 40.0% of total).
CyPass is associated with 16 research studies, including "An Observational Multicenter Clinical Study to Assess the Long-Term Safety of the Transcend CyPass Micro-Stent Glaucoma Implant in Patients With primary Open Angle Glaucoma who have Completed participation in the COMPASS Trial (A02803 Transcend Cypass)" ($453,361).